HUP9901908A2 - p16 Expressziós konstrukciók és alkalmazásuk rákterápiában - Google Patents

p16 Expressziós konstrukciók és alkalmazásuk rákterápiában

Info

Publication number
HUP9901908A2
HUP9901908A2 HU9901908A HUP9901908A HUP9901908A2 HU P9901908 A2 HUP9901908 A2 HU P9901908A2 HU 9901908 A HU9901908 A HU 9901908A HU P9901908 A HUP9901908 A HU P9901908A HU P9901908 A2 HUP9901908 A2 HU P9901908A2
Authority
HU
Hungary
Prior art keywords
cells
cancer
function
pinworm
nucleic acid
Prior art date
Application number
HU9901908A
Other languages
English (en)
Inventor
Xiaomei Jin
Jack Roth
Original Assignee
Board Of Regents The University Of Texas System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Board Of Regents The University Of Texas System filed Critical Board Of Regents The University Of Texas System
Publication of HUP9901908A2 publication Critical patent/HUP9901908A2/hu
Publication of HUP9901908A3 publication Critical patent/HUP9901908A3/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

A találmány szerinti megőldás a tűmőrbiőlógia tárgykörébe tartőzik. Atalálmány tárgyát egy tűmőrszűpresszőrt kódőló nűkleinsav és annaktűmőrnövekedés gátlására történő alkalmazása képezi. A találmánytárgyát képezi tővábbá egy - eűkarióta sejtekben működőképes prőmőtertés p16 prőteint kódőló nűkleinsavat tartalmazó - virális expresszióskőnstrűkció; a találmány szerinti expressziós kőnstrűkciót tartalmazógyógyászati készítmény és reagenskészlet; valamint eljárásők p16fűnkció tekintetében hiányős sejtek p16 fűnkciójának helyreállítására; sejtek p16 fűnkciójának gátlására; rákban szenvedő emlős kezelésére;tővábbá mintában lévő ráksejtek kiműtatására. A találmány szerintimegőldás alkalmas tüdőrák és más - p16 prőteinnel összefüggő -rákbetegségek (példáűl húgyhólyagrák és melanóma) kezelésére, illetveráksejtek kiműtatására. ŕ
HU9901908A 1995-07-17 1996-07-17 P16 expression constructs and their application in cancer therapy HUP9901908A3 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US50288195A 1995-07-17 1995-07-17

Publications (2)

Publication Number Publication Date
HUP9901908A2 true HUP9901908A2 (hu) 1999-09-28
HUP9901908A3 HUP9901908A3 (en) 2000-02-28

Family

ID=23999797

Family Applications (1)

Application Number Title Priority Date Filing Date
HU9901908A HUP9901908A3 (en) 1995-07-17 1996-07-17 P16 expression constructs and their application in cancer therapy

Country Status (15)

Country Link
US (1) US6251871B1 (hu)
EP (1) EP0839207A2 (hu)
JP (1) JPH11510380A (hu)
KR (1) KR19990029028A (hu)
CN (1) CN1203632A (hu)
AU (1) AU724324B2 (hu)
BR (1) BR9609853A (hu)
CA (1) CA2227193A1 (hu)
CZ (1) CZ15498A3 (hu)
HU (1) HUP9901908A3 (hu)
NO (1) NO980218L (hu)
NZ (1) NZ313828A (hu)
PL (1) PL324750A1 (hu)
SK (1) SK6598A3 (hu)
WO (1) WO1997003635A2 (hu)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6689561B1 (en) * 1994-04-14 2004-02-10 The Regents Of The University Of California Tumor suppressor gene and methods for detection of cancer, monitoring of tumor progression and cancer treatment
US7163925B1 (en) * 1995-07-17 2007-01-16 Board Of Regents, The University Of Texas System p16 expression constructs and their application in cancer therapy
GB9519275D0 (en) 1995-09-21 1995-11-22 Univ Dundee Substances and their therapeutic use
WO1997012623A1 (en) † 1995-10-06 1997-04-10 Arch Development Corporation Methods and compositions for viral enhancement of cell killing
DE1007662T1 (de) * 1997-02-20 2001-04-19 Hepavec Ag Fuer Gentherapie Verfahren zur induktion von apoptotischen zelltot in malignanten zellen ,durch verminderung der rb zur apoptosis induzierende proteinen ratio
HUP0001550A3 (en) 1997-03-14 2001-02-28 Unilever Nv Frozen food product
US6489305B1 (en) 1998-05-08 2002-12-03 Canji, Inc. Methods and compositions for the treatment of ocular diseases
KR19990086165A (ko) * 1998-05-26 1999-12-15 성재갑 Cdk４ 의 저해제인 p16의 카복시말단이 절단된 결손형cδp１６ 단백질, 그의 유전자
US6420345B1 (en) * 1999-03-01 2002-07-16 Cell Genesys, Inc. Methods and reagents for inhibiting angiogenesis
US20040266834A1 (en) * 1999-10-14 2004-12-30 Copland John A. Thiazolidinediones alone or in cabination with other therapeutic agents for cancer therapy
US7223406B2 (en) 2000-07-21 2007-05-29 The Regents Of The University Of California Methods and compositions for preventing and treating male erectile dysfunction and female sexual arousal disorder
WO2002007757A2 (en) * 2000-07-21 2002-01-31 Lue Tom F Prevention and treatment of sexual arousal disorders
US20040005294A1 (en) * 2002-02-25 2004-01-08 Ho-Young Lee IGFBP-3 in the diagnosis and treatment of cancer
US20030219696A1 (en) * 2002-05-23 2003-11-27 Moreland Gerald W. Method and apparatus for preventing backflow in dental saliva evacuators
CN101507822B (zh) 2003-11-24 2012-06-06 坎吉有限公司 皮肤瘢痕形成的减少
EP1799230B1 (en) 2004-08-27 2012-11-21 Cyclacel Limited Purine and pyrimidine cdk inhibitors and their use for the treatment of autoimmune diseases
US7695965B2 (en) * 2006-03-02 2010-04-13 Cythera, Inc. Methods of producing pancreatic hormones
CN103293308B (zh) * 2013-05-24 2014-11-26 尉军 一种检测肿瘤标志物p16抗原表位氨基酸序列及应用
CN104558147B (zh) * 2015-01-20 2017-11-07 刘林林 一种检测宫颈癌标志物cdkn2a抗原表位多肽及应用
EP3295181A4 (en) 2015-05-14 2018-11-14 Expression Pathology, Inc. Srm/mrm assay for the fibroblast growth factor receptor 2 (fgfr2) protein
KR102062149B1 (ko) * 2015-05-22 2020-01-03 익스프레션 패톨로지, 인크. 사이클린-의존성 키나제 억제제 2A(p16) 단백질에 대한 SRM/MRM 분석법

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0273085A1 (en) 1986-12-29 1988-07-06 IntraCel Corporation A method for internalizing nucleic acids into eukaryotic cells
US5399346A (en) 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
US5747469A (en) 1991-03-06 1998-05-05 Board Of Regents, The University Of Texas System Methods and compositions comprising DNA damaging agents and p53
DE69333043T2 (de) 1992-10-16 2004-05-06 Cold Spring Harbor Laboratory Umlagerung des cyclin komlexes und seine darauf bezogenen anwendungen
US6211334B1 (en) 1992-10-16 2001-04-03 Cold Spring Harbor Cell-cycle regulatory proteins, and uses related thereto
FR2705686B1 (fr) 1993-05-28 1995-08-18 Transgene Sa Nouveaux adénovirus défectifs et lignées de complémentation correspondantes.
MY119195A (en) * 1993-12-30 2005-04-30 Shell Int Research Lightweight, wide-bodied compliant tower.
EP0702730A4 (en) 1994-03-18 1997-05-07 Univ Utah Res Found COREWAY MUTTATIONS IN THE MTS GENE AND METHODS FOR DETECTING AN APPROXIMATION OF CANCER IN THE MTS GENE
AU694502B2 (en) 1994-03-18 1998-07-23 Myriad Genetics, Inc. Mts gene, mutations therein, and methods for diagnosing cancer using mts gene sequence
US6689561B1 (en) * 1994-04-14 2004-02-10 The Regents Of The University Of California Tumor suppressor gene and methods for detection of cancer, monitoring of tumor progression and cancer treatment
KR970702915A (ko) 1994-04-29 1997-06-10 린다 버겐 종양 세포의 치료 감응성 향상 방법(Enhancing The Sensitivity of Tumor Cells to Therapies)
DE19501073A1 (de) * 1995-01-16 1996-08-01 Nova C O R D Ag Bildverarbeitungsverfahren zur Ermittlung der Strukturfestigkeit eines Prüfobjektes mit diffus streuender Oberfläche
WO1996025507A2 (en) * 1995-02-17 1996-08-22 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Methods of preparation and use of recombinant adenoviral vectors
US5672508A (en) 1996-01-23 1997-09-30 Mitotix, Inc. Inhibitors of cell-cycle progression, and uses related thereto
CA2282683A1 (en) 1997-02-18 1998-08-20 Canji, Inc. Combined tumor suppressor gene therapy and chemotherapy in the treatment of neoplasms

Also Published As

Publication number Publication date
CA2227193A1 (en) 1997-02-06
KR19990029028A (ko) 1999-04-15
EP0839207A2 (en) 1998-05-06
PL324750A1 (en) 1998-06-08
AU6647896A (en) 1997-02-18
JPH11510380A (ja) 1999-09-14
CZ15498A3 (cs) 1998-07-15
SK6598A3 (en) 1998-09-09
NZ313828A (en) 1999-02-25
US6251871B1 (en) 2001-06-26
AU724324B2 (en) 2000-09-14
NO980218D0 (no) 1998-01-16
BR9609853A (pt) 1999-10-13
HUP9901908A3 (en) 2000-02-28
WO1997003635A2 (en) 1997-02-06
CN1203632A (zh) 1998-12-30
NO980218L (no) 1998-03-16
WO1997003635A3 (en) 1997-05-15

Similar Documents

Publication Publication Date Title
HUP9901908A2 (hu) p16 Expressziós konstrukciók és alkalmazásuk rákterápiában
HUP0003533A2 (hu) Interleukin-18-at kötő fehérjék, előállításuk és alkalmazásuk
HUP0002095A2 (hu) Vegyületek prosztatarák immunterápiás kezelésére és alkalmazásuk
MXPA02000192A (es) Composiciones y metodos para la terapia y diagnostico de cancer de pulmon.
HUP0104717A2 (hu) Készítmények és eljárások petefészekrák terápiájára és diagnózisára
CY1105818T1 (el) Χρησεις του et743 στην θepαπευτικη αγωγη του καρκινου
DK1992695T3 (da) Lectin-transmembran-antigen af type C udtrykt i human prostatacancer og avendelser deraf
ATE194660T1 (de) Veraendertes gen bei menschlichem colorektalem- krebs
ATE347585T1 (de) In-vitro wachstum von langerhans'schen inseln und ihre verwendungen
HUP0105058A2 (hu) Perifériás benzodiazepin receptorhoz kötődő anyag alkalmazása kutánstressz kezelésére
HUP9800028A2 (hu) Több tumor esetében rendellenes sejtszaporodás előidézésében közrejátszó gének
AU3368497A (en) Human dnase i hyperactive variants
PT1157041E (pt) Anticorpos para terapia e diagnostico de cancro
WO2000060077A3 (en) Compounds for therapy and diagnosis of lung cancer and methods for their use
DK1368060T3 (da) HMGB1-proteininhibitorer og/eller antagonister til behandlingen af vaskulære sygdomme
DK43890A (da) Nucleinsyre, vektorer og celler indeholdende den, derudfra fremstillede produkter og disses anvendelse
WO2000037643A3 (en) Compounds for immunotherapy and diagnosis of colon cancer and methods for their use
AU2001247968A1 (en) Use of asiatic acid or asiaticoside for treatment of cancer
DK208987A (da) Polypeptider og antistoffer, som er karakteristiske for papillomvirus, og deres anvendelse ved diagnostiske metoder og i vacciner
EP0689586B8 (en) Vpr function and activity
EA199800692A1 (ru) Изолируемые смеси из семян eugenia jambolana lamarck, способы их получения, способ получения оксамата натрия, лекарственные средства для профилактики и лечения диабета и применение указанных смесей, их компонентов и оксамата натрия для получения этих лекарственных средств
ES8706827A1 (es) Procedimiento para preparar polipeptidos.
WO2002067771A3 (en) Chemokine receptors and disease
HUP9800613A2 (hu) Humán Fas-antigén elleni humanizált antitest
ES8707565A1 (es) Un procedimiento para producir un anticuerpo monoclonal